Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Rituximab in Progressive Multiple Sclerosis
NCT02545959Phase 2Completed
- Sponsor
- Centre Hospitalier de Pau
- Start
- Nov 2015
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in multiple sclerosis (MS), sponsored by Centre Hospitalier de Pau. Started Nov 2015; status: completed.
02
Drugs
rituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02545959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02545959.